Introduction
The U.S. Consumer Product Safety materials, products that emit radiation Commission (CPSC) is an independent reg-(e.g., microwave ovens), and automobiles ulatory agency that was created in 1973. (1) . Some low-level exposures that the The CPSC has jurisdiction over more than CPSC has investigated include: asbestos in 15,000 types of consumer products used in plaster products (2) ; formaldehyde emisand around the home or by children, except sions from urea-formaldehyde foam insulaitems such as food, drugs, cosmetics, medical tion (3) and pressed wood products (4); devices, pesticides, certain radioactive tris (2,3-dibromopropyl) Manuscript received at EHP7 March 1997; accepted 1 July 1997.
The opinions expressed in this paper are those of the author. They do not necessarily reflect the views of the Commission. This paper was prepared in the course of the official duties of the author as an employee of the U.S. Consumer Product Safety Commission. It is in the public domain and may be freely copied and reproduced in accordance with the provisions of 17 retardant in children's sleepwear (5); nitrosamines in infant pacifiers (6,7); CO and NO2 emissions from combustion appliances (8, 9) ; polycyclic aromatic hydrocarbon emissions from wood stoves (10); methylene chloride in paint removers and other products (11) (12) (13) (14) ; volatile organic compound emissions from carpets (15) and carpet cushions (16) ; and dioxin in paper products (17 (20) . The surface area correction is used for animal-to-human extrapolation; surface area correction is used by the U.S. EPA (22) but not by the U.S. FDA (25) . Pharmacokinetic modeling may be used to extrapolate from route to route, high to low dose, or one exposure regimen to another, but not for animal-to-human extrapolation (20) . In contrast to the U.S. EPA (22) , an increased incidence of benign tumors may contribute to a finding of sufficient evidence of carcinogenicity in animals if the benign tumors have the potential to progress to malignancy (20) . Tumors at independent sites in the same laboratory animal are considered separate responses and therefore could support a finding of sufficient evidence of carcinogenicity in animals (20) . These differences are subject to change, however, as new risk-assessment methods are adopted (24, 26) .
The default procedure for assessing noncancer end points is essentially a safety factor approach (20) . For both cancer and noncancer end points, an acceptable daily intake (ADI) is calculated. A substance is considered hazardous under the FHSA if the ADI is exceeded during "reasonably foreseeable handling and use" (19) .
Reasons for the differences in risk assessment procedures among federal agencies are discussed in detail elsewhere (20, 23, 27) . Some of these differences reflect differences in the agencies' missions and the statutes that they administer; others are in areas of scientific uncertainty (20, 23, 27) . Although they use different procedures, the cancer potency estimates derived by the CPSC, the U.S. EPA, and the U.S. FDA generally fall within a 10-fold range (25) . The difference in potency estimates is mainly attributable to the method of animal-to-human extrapolation (surface area or body weight) and choice of risk metric (MLE or upper bound) ( Table 1) . The CPSC works closely with other federal agencies on issues that cross jurisdictional boundaries, such as methylene chloride (28) , dioxin in paper products (25) , and indoor air quality (29) , and has participated in efforts to harmonize riskassessment procedures among federal agencies (30) . (12) (13) (14) . Methylene chloride is metabolized by two pathways: a glutathione S-transferase pathway that is believed to activate methylene chloride and a mixed-function oxidase pathway that may be considered to detoxify. In this case, the dose surrogate was the amount of methylene chloride metabolized by the glutathione S-transferase pathway in the the Environmental Health Perspectives * Vol 106, Supplement 1 * February 1998 target tissue. Because the risk in humans was estimated from animal studies, PBPK models were developed and validated for humans as well as for animals (12) (13) (14) .
DNA repair is another type of recovery process that repairs damage induced by carcinogens. Thus, some authors have proposed the use of DNA adducts as measures of internal dose in risk assessment (32) (33) (34) (35) (36) (37) . As with PBPK models, the choice of dose surrogate is a critical issue. The particular adduct used as the the dose surrogate should be the cause of the tumors, the tumor response should be direcdy related to the adduct level, and the relationship between adduct level and tumor response should be constant with dose (36, 37) . Many chemical carcinogens induce multiple DNA adducts. For example, alkylating agents induce a spectrum of adducts, including 06-alkylguanine and 0 alkylthymine (38) (39) (40) (41) . 0 -alylguanine is considered procarcinogenic in the induction of nervous system (42) and mammary (43) tumors in animals. However, in rats continuously exposed to diethylnitrosamine, 04_ ethylthymine accumulated in hepatocyte DNA, whereas 06-ethylguanine levels declined to nondetectable levels because of the more efficient repair of 06-ethylguanine (34, 35) . Therefore, 04-ethylthymine may be more important than 06-ethylguanine in the induction of hepatocellular tumors in rats (34, 35) .
Once the procarcinogenic adduct is identified, other issues remain: a) DNA adducts may not be uniformly distributed throughout the genome (44); b) DNA repair may be targeted to actively transcribed genes (45) and to the transcribed strand (46); c) mutational hot spots appear to play an important role in carcinogenesis in humans (47) (48) (49) ; d) cell replication, the rate of which may vary among different organs and cell types (33, 35) , is required for mutagenesis to occur. Therefore, there might not be a direct relationship between adduct levels in bulk DNA and tumor response (33) (34) (35) (36) (37) .
Third, if low doses of toxic agents induce apparently beneficial responses (e.g., enhanced longevity, lower incidence of disease), how does and/or could the CPSC address this? The FHSA only defines toxic and hazardous. It does not define nontoxic or nonhazardous and it does not address beneficial effects. Therefore, beneficial effects per se could not be addressed under the FHSA: only the potential hazards could be addressed. Any product that daimed a beneficial effect could be under the jurisdiction of other federal agencies.
There are at least two situations in which a low dose of a toxic agent could induce apparently beneficial effects. In one situation the agent has no effect or a beneficial effect at low levels and is toxic at higher levels; that is, a threshold or a J-shaped dose-response curve, respectively. Whereas regulatory decisions under the FHSA are risk based, the key issue is whether the exposures that would occur during "reasonably foreseeable handling and use" (19) would present a hazard.
In the second situation a low-level exposure at subtoxic doses could induce a defense mechanism that protects against a subsequent potentially toxic exposure; the risk would depend on a prior exposure at the lower dose. The pertinent issue is whether the prior low-level exposure is likely to occur during "reasonably foreseeable handling and use" (19) . One might also consider whether the ability to induce the appropriate defense mechanism is universal or whether some individuals might be deficient in the inducible defense mechanism and thus be more susceptible.
Conclusions
The CPSC chronic hazard guidelines were issued in 1992 (20) . They were not intended to be applied mechanically. Rather, the guidelines are sufficiently flexible to allow professional judgment and the latest science to be incorporated into the risk-assessment process. The default assumptions are meant to be used only in the absence of evidence to the contrary. Alternative (50, 51 ). An early step in TCDD-induced carcinogenesis is believed to be binding to the aryl hydrocarbon receptor, which leads to alterations in the expression of certain genes. Extensive study of the effects of TCDD on gene expression suggests that receptor-mediated mechanisms may result in either linear or nonlinear responses at low doses (52, 53) . Therefore, the knowledge that a certain carcinogen is nongenotoxic or acts through a receptor is in itself insufficient to abandon the default procedure for high-to-low dose extrapolation.
